INTERNATIONAL CONFERENCE
ACUTE LYMPHOBLASTIC LEUKAEMIA

Berlin, Germany
May 17-19, 2019
Chairs: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

Friday, May 17, 2019

09:00–09:05	**Welcome**	Adele Fielding & Hervé Dombret

INTRODUCTORY LECTURES
Chairs: Charles Mullighan (Memphis) & Elizabeth Macintyre (Paris)

09:05-09:20	Autoimmunity checkpoints in B-Cell lineage ALL	Markus Müschen (Los Angeles)
09:20-09:25	*Discussion*	
09:25-09:40	Thymus autonomous T cell development and T-cell acute lymphoblastic leukemia	Hans-Reimer Rodewald (Heidelberg)
09:40-09:45	*Discussion*	
09:45-10:15	***Coffee Break***	

SESSION I – MASTER PATHWAYS/TARGETS IN B-CELL PRECURSOR ALL
Chair: Monika Brüggemann (Kiel)

10:15-10:35	New genetic entities in BCP-ALL	Emmanuelle Clappier (Paris)
10:35-10:40	*Discussion*	
10:40-11:00	The revised taxonomy of B-ALL	Charles Mullighan (Memphis)
11:00-11:05	*Discussion*	
11:05-11:25	Origin, evolution and targeting of childhood leukaemia	Tariq Enver (London)
11:25-11:30	*Discussion*	
11:30-11:37	*IKZF1 deletion with co-existed RAS pathway mutations associated with inferior outcome in pediatric B-ALL in Taiwan*	*Ying-Jung Huang (Taiwan)*
11:37-11:40	*Discussion*	
11:40-12:00	*Panel discussion*	

ROUND TABLE 1: ALL PREDISPOSITION AND EARLY INITIATION
Chair: Franco Locatelli (Rome)

12:00-12:15	The inherited predisposition to childhood ALL	Jun Yang (Memphis)

12:15-12:30	MLL-rearranged acute lymphoblastic leukemia	Pablo Menendez (Barcelona)
12:30-12:50	*Discussion*	

SHORT COMMUNICATIONS:

12:50-12:57	*Aberrant DNA hypermethylation signature of the LIC compartment in MLL rearranged Acute Lymphoblastic Leukaemia*	*Quentin Heydt (London)*
12:57:13:00	*Discussion*	
13:00-13:07	*Tumor suppression in T-ALL via Ikaros-dependent direct global rearrangement of enhancer and super-enhancer architecture*	*Sinisa Dovat (Hershey)*
13:07-13:10	*Discussion*	
13:10-13:17	*Clinical value of mismatch repair gene deletions in childhood relapsed B-Cell precursor Acute Lymphoblastic Leukemia*	*Malwine Pogodzinski (Berlin)*
13:17-13:20	*Discussion*	

13:20-14:20 Lunch

SESSION II – MASTER PATHWAYS/TARGETS IN T-ALL
Chair: Jean Soulier (Paris)

14:20-14:35	TCR and T-ALL	Elizabeth Macintyre (Paris)
14:35-14:40	*Discussion*	
14:40-14:55	Targeting oncogenic NOTCH1 signaling in T-cell acute lymphoblastic leukemia	Jan Cools (Leuven)
14:55-15:00	*Discussion*	
15:00-15:15	IL7R AND PTEN	João Barata (Lisbon)
15:15-15:20	*Discussion*	
15:20-15:35	JAK/STAT signaling in T-ALL	Pieter Van Vlierberghe (Ghent)
15:35-15:40	*Discussion*	
15:40-15:55	Deletion 6q impairs ribosomal and mitochondrial functions to drive leukemia progression in T-ALL	Jean Soulier (Paris)
15:55-16:00	*Discussion*	
16:00-16:07	*The nucleotide kinase Nadk constitutes a metabolic vulnerability of NOTCH1-driven T-ALL*	*Etienne De Braekeleer (Cambridge)*
16:07-16:10	*Discussion*	
16:10-16:30	*Panel discussion*	

16:30-17:00 Coffee Break

SESSION III – INDIVIDUAL MANAGEMENT OF ALL
Chair: Dieter Hoelzer (Frankfurt)

17:00-17:15	Precision diagnosis for tailored therapy	Jean-Pierre Bourquin (Zürich)
17:15-17:20	*Discussion*	
17:20-17:35	Metabolism, disposition, and toxicity of ALL drugs	Mary Relling (Memphis)
17:35-17:40	*Discussion*	
17:40-17:55	Adolescents and young adults	Josep-Maria Ribera (Barcelona)
17:55-18:00	*Discussion*	
18:00-18:15	Older patients	Nicola Gökbuget (Frankfurt)
18:15-18:20	*Discussion*	
18:20-18:27	*Commonly used chemotherapy drugs differentially determine microenvironment-mediated protection, via mitochondrial transfer, to B-precursor Acute Lymphoblastic Leukaemia cells*	*Richard Burt (London)*
18:27-18:30	*Discussion*	
18:30 -18:50	*Panel discussion*	

19:00-20:30 ***Mentored poster walks and welcome get-together***
- Biology poster walk: Emmanuelle Clappier (Paris) and Jan Cools (Leuven)
- Clinical poster walk: Josep-Maria Ribera (Barcelona) and Nicola Gökbuget (Frankfurt)

Saturday, May 18, 2019

07:50-8:50 **Simultaneous Meet the Expert sessions:**

- L-Asparaginase efficacy monitoring	Nicolas Boissel (Paris)
- CNS involvement prophylaxis and therapy	Mark Litzow (Rochester)
- Minimal Residual Disease, assessment techniques	Monika Brüggemann (Kiel)

Breakfast will be available from 8:30

09:00-10:00 **SATELLITE SYMPOSIUM**
Ph+ ALL : time for deeper control
Chair: Oliver Ottmann
Speakers: Heike Pfeifer and Oliver Ottmann

This educational symposium is organized and funded by Incyte.

10:00-10:30 ***Coffee break***

SESSION IV – IMMUNOTHERAPY FOR ALL
Chair: Nicola Gökgubet (Frankfurt)

10:30-10:45	CD20 in ALL	Adele Fielding (London)
10:45-10:50	*Discussion*	

10:50-11:05	Bispecific T-cell therapy (BiTEs)	Max Topp (Würzburg)
11:05-11:10	*Discussion*	
11:10-11:25	Poor penetration of existing effective chemo-immunotherapy for the treatment of older newly diagnosed and refractory-relapsed (R-R) ALL	Hagop Kantarjian (Houston)
11:25-11:30	*Discussion*	
11:30-11:45	Chimeric antigen receptor (CAR) gene-modified T cells	Claudia Rössig (Münster)
11:45-11:50	*Discussion*	
11:50-12:05	Novel adoptive cell therapies	Rupert Handgretinger (Tübingen)
12:05-12:10	*Discussion*	

KEYNOTE LECTURE
Chair: Hervé Dombret (Paris)

12:10-12:25	BiTEs, ADC, CAR-T, allogeneic HSCT, what's first?	Dieter Hoelzer (Frankfurt)
12:25-12:30	*Discussion*	
12:30-12:37	*Novel agents for the treatment of high-risk Acute Lymphoblastic Leukaemia in children*	*Richard Lock (Sydney)*
12:37-12:40	*Discussion*	
12:40-13:00	*Panel discussion*	

13:00-14:00 Lunch

ROUND TABLE 2: ADULT VS PAEDIATRIC OPINIONS
Should MRD overcome baseline factors in risk assessment?
Chair: Monika Brüggemann (Kiel)

14:00-14:15	Adult opinion	Renato Bassan (Venice)
14:15-14:30	Integrating, balancing and disregarding risk factors in paediatric leukaemia	Anthony Moorman (Newcastle)
14:30-14:45	*Discussion*	

14:45-15:15 Coffee Break

SESSION V – ISSUES IN ALLOGENEIC HSCT
Chair: Jan Cornelissen (Rotterdam)

15:15-15:30	Indications for allogeneic HSCT in adult Acute Lymphoblastic Leukemia	Mark Litzow (Rochester)
15:30-15:35	*Discussion*	
15:35-15:50	Post allograft relapse of ALL	David Marks (Bristol)
15:50-15:55	*Discussion*	
15:55-16:10	New haplo-identical HSCT modalities	Franco Locatelli (Rome)
16:10-16:15	*Discussion*	

16:15-16:22	*Minimal residual disease is the most important risk factor in pediatric T-Cell Acute Lymphoblastic Leukemia: a collaborative study of the biological committee of the leukemia group of the spanish hematology and oncology pediatric society*	*Mireia Camós (Barcelona)*
16:22-16:25	*Discussion*	
16:25-16:45	*Panel discussion*	

17:00-18:00 Simultaneous Meet the Expert sessions:

- Practical issues with blinatumomab and inozutumab ozogamicin — Hagop Kantarjian (Houston)
- Post-transplant management of Ph-positive ALL — Oliver Ottmann (Cardiff)
- Reduced toxicity conditioning for older ALL HSCT — Jan Cornelissen (Rotterdam)

Sunday, May 19, 2019

SESSION VI – PHILADELPHIA CHROMOSOME-POSITIVE ALL
Chair: Adele Fielding (London)

08:00-08:15	Risk factors in Ph+ ALL	Sabina Chiaretti (Rome)
08:15-08:20	*Discussion*	
08:20-08:35	Optimal use of TKIs to treat Ph+ ALL?	Hervé Dombret (Paris)
08:35-08:40	*Discussion*	
08:40-08:55	Synopsis of presentation : «Are next generation TKI better for philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)?»	Oliver Ottmann (Cardiff)
08:55-09:00	*Discussion*	
09:00-09:15	Minimal residual disease monitoring in Ph+ ALL	Jan Zuna (Prague)
09:15-09:20	*Discussion*	
09:20-09:27	*Prospective diagnosis of Ph-like ALL enables efficient TKI therapy in patients with ABL-class alterations*	*Ilaria Tanasi (Verona)*
09:27-09:30	*Discussion*	
09:30-09:50	*Panel discussion*	

09:50-10:20 Coffee Break

ROUND TABLE 3: DIFFICULT TO TREAT ALL SUBGROUPS
Chair: Mark Litzow (Rochester)

10:20-10:35	Diagnosis and treatment of BCR-ABL1-like/philadelphia-like ALL; hurdles and opportunities	Monique den Boer (Utrecht)
10:35-10:50	How to treat relapsing childhood ALL in the immuntherapy era?	Pierre-Simon Rohrlich (Nice)
10:50-11:05	*Discussion*	

SESSION VII – T-CELL ALL/LL
Chair: David Marks (Bristol)

11:05-11:20	IL7 signaling mutations induce steroid resistance in T-cell acute lymphoblastic leukemia	Jordy Van Der Zwet (Utrecht)
11:20-11:25	*Discussion*	
11:25-11:40	Nelarabine in T-ALL/LL	Clare Rowntree (Cardiff)
11:40-11:45	*Discussion*	
11:45-12:00	Novel therapies for T-ALL/LL	Nicolas Boissel (Paris)
12:00:12:05	*Discussion*	
12:05-12:20	Place of allogeneic HSCT in T-ALL/LL	Jan Cornelissen (Rotterdam)
12:20-12:25	*Discussion*	
12:25-12:32	*An in vivo genome wide CRISPR screen to identify mechanisms underlying drug resistance to induction therapy in T-ALL*	*Frederik van Delft (Newcastle upon Tyne)*
12:32-12:35	*Discussion*	
12:35-12:55	*Panel discussion*	
12:55-13:00	**Closing Remarks**	Mark Litzow (Rochester)

MEETING CLOSURE